Abstract
Predicting and mitigating the risk of neuropsychological deficits are essential to improve quality of life and long-term psychosocial, educational, and employment outcomes of the growing cohort of pediatric brain tumor survivors. A review of existing research on disease- and treatment-related variables, individual characteristics, and environmental factors related to neuropsychological outcomes in this population is presented. While the nature and severity of deficits experienced by survivors are variable, core cognitive functions such as attention, processing speed, working memory, psychomotor skills, and new learning appear highly vulnerable to disruption, and in turn, underlie declines in general intellectual and academic functioning. Empirically validated interventions are discussed, along with novel approaches for reducing neuropsychological morbidity, such as risk-adapted treatments and exploration of neuroprotective agents and neuronal repair activities. Focus on the subgroups of pediatric brain tumor patients at highest risk of poor outcomes is necessary to direct early and effective interventions in order to improve long-term neuropsychological functioning, and ultimately, the quality of survivorship.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zeltzer LK, Recklitis C, Buchbinder D, Zebrack B, Casillas J, Tsao JC, et al. Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2396–404.
Palmer SL. Neurodevelopmental impact on children treated for medulloblastoma: a review and proposed conceptual model. Dev Disabil Res Rev. 2008;14(3):203–10.
Askins MA, Moore 3rd BD. Preventing neurocognitive late effects in childhood cancer survivors. J Child Neurol. 2008;23(10):1160–71.
Dennis M, Spiegler BJ, Hetherington CR, Greenberg ML. Neuropsychological sequelae of the treatment of children with medulloblastoma. J Neurooncol. 1996;29(1):91–101.
Mabbott DJ, Spiegler BJ, Greenberg ML, Rutka JT, Hyder DJ, Bouffet E. Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J Clin Oncol. 2005;23(10):2256–63.
Mabbott DJ, Rovet J, Noseworthy MD, Smith ML, Rockel C. The relations between white matter and declarative memory in older children and adolescents. Brain Res. 2009;1294:80–90.
Robinson KE, Kuttesch JF, Champion JE, Andreotti CF, Hipp DW, Bettis A, et al. A quantitative meta-analysis of neurocognitive sequelae in survivors of pediatric brain tumors. Pediatr Blood Cancer. 2010;55(3):525–31.
Robinson KE, Fraley CE, Pearson MM, Kuttesch Jr JF, Compas BE. Neurocognitive late effects of pediatric brain tumors of the posterior fossa: a quantitative review. J Int Neuropsychol Soc. 2013;19(1):44–53.
Mabbott DJ, Penkman L, Witol A, Strother D, Bouffet E. Core neurocognitive functions in children treated for posterior fossa tumors. Neuropsychology. 2008;22(2):159–68.
Patel SK, Mullins WA, O’Neil SH, Wilson K. Neuropsychological differences between survivors of supratentorial and infratentorial brain tumours. J Intellect Disabil Res. 2011;55(1):30–40.
Merchant TE, Lee H, Zhu J, Xiong X, Wheeler G, Phipps S, et al. The effects of hydrocephalus on intelligence quotient in children with localized infratentorial ependymoma before and after focal radiation therapy. J Neurosurg. 2004;101(2 Suppl):159–68.
Reimers TS, Ehrenfels S, Mortensen EL, Schmiegelow M, Sonderkaer S, Carstensen H, et al. Cognitive deficits in long-term survivors of childhood brain tumors: identification of predictive factors. Med Pediatr Oncol. 2003;40(1):26–34.
Jalali R, Mallick I, Dutta D, Goswami S, Gupta T, Munshi A, et al. Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77(4):974–9.
Beebe DW, Ris MD, Armstrong FD, Fontanesi J, Mulhern R, Holmes E, et al. Cognitive and adaptive outcome in low-grade pediatric cerebellar astrocytomas: evidence of diminished cognitive and adaptive functioning in National Collaborative Research Studies (CCG 9891/POG 9130). J Clin Oncol. 2005;23(22):5198–204.
Ris MD, Beebe DW, Armstrong FD, Fontanesi J, Holmes E, Sanford RA, et al. Cognitive and adaptive outcome in extracerebellar low-grade brain tumors in children: a report from the Children’s Oncology Group. J Clin Oncol. 2008;26(29):4765–70.
Law N, Greenberg M, Bouffet E, Taylor MD, Laughlin S, Strother D, et al. Clinical and neuroanatomical predictors of cerebellar mutism syndrome. Neuro Oncol. 2012;14(10):1294–303.
Palmer SL, Hassall T, Evankovich K, Mabbott DJ, Bonner M, Deluca C, et al. Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. Neuro Oncol. 2010;12(12):1311–7.
Spiegler BJ, Bouffet E, Greenberg ML, Rutka JT, Mabbott DJ. Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol. 2004;22(4):706–13.
Grill J, Renaux VK, Bulteau C, Viguier D, Levy-Piebois C, Sainte-Rose C, et al. Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys. 1999;45(1):137–45.
Di Pinto M, Conklin HM, Li C, Merchant TE. Learning and memory following conformal radiation therapy for pediatric craniopharyngioma and low-grade glioma. Int J Radiat Oncol Biol Phys. 2012;84(3):e363–9.
Riva D, Giorgi C, Nichelli F, Bulgheroni S, Massimino M, Cefalo G, et al. Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology. 2002;59(1):48–53.
Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352(10):978–86.
Sands SA, Oberg JA, Gardner SL, Whiteley JA, Glade-Bender JL, Finlay JL. Neuropsychological functioning of children treated with intensive chemotherapy followed by myeloablative consolidation chemotherapy and autologous hematopoietic cell rescue for newly diagnosed CNS tumors: an analysis of the Head Start II survivors. Pediatr Blood Cancer. 2010;54(3):429–36.
Reddick WE, Glass JO, Palmer SL, Wu S, Gajjar A, Langston JW, et al. Atypical white matter volume development in children following craniospinal irradiation. Neuro Oncol. 2005;7(1):12–9.
Mulhern RK, White HA, Glass JO, Kun LE, Leigh L, Thompson SJ, et al. Attentional functioning and white matter integrity among survivors of malignant brain tumors of childhood. J Int Neuropsychol Soc. 2004;10(2):180–9.
Mabbott DJ, Noseworthy MD, Bouffet E, Rockel C, Laughlin S. Diffusion tensor imaging of white matter after cranial radiation in children for medulloblastoma: correlation with IQ. Neuro Oncol. 2006;8(3):244–52.
Monje ML, Vogel H, Masek M, Ligon KL, Fisher PG, Palmer TD. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol. 2007;62(5):515–20.
Nagel BJ, Delis DC, Palmer SL, Reeves C, Gajjar A, Mulhern RK. Early patterns of verbal memory impairment in children treated for medulloblastoma. Neuropsychology. 2006;20(1):105–12.
de Ruiter MA, van Mourik R, Schouten-van Meeteren AY, Grootenhuis MA, Oosterlaan J. Neurocognitive consequences of a paediatric brain tumour and its treatment: a meta-analysis. Dev Med Child Neurol. 2013;55(5):408–17.
Palmer SL, Gajjar A, Reddick WE, Glass JO, Kun LE, Wu S, et al. Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology. 2003;17(4):548–55.
Dennis M, Spiegler BJ, Hetherington R. New survivors for the new millennium: cognitive risk and reserve in adults with childhood brain insults. Brain Cogn. 2000;42(1):102–5.
Barahmani N, Carpentieri S, Li XN, Wang T, Cao Y, Howe L, et al. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol. 2009;11(3):292–300.
Peterson CC, Drotar D. Family impact of neurodevelopmental late effects in survivors of pediatric cancer: review of research, clinical evidence, and future directions. Clin Child Psychol Psychiatry. 2006;11(3):349–66.
Carlson-Green B, Morris RD, Krawiecki N. Family and illness predictors of outcome in pediatric brain tumors. J Pediatr Psychol. 1995;20(6):769–84.
Penkman L, Scott-Lane L. Prophylactic academic intervention for children treated with cranial radiation therapy. Dev Neurorehabil. 2007;10(1):19–26.
Butler RW, Copeland DR, Fairclough DL, Mulhern RK, Katz ER, Kazak AE, et al. A multicenter, randomized clinical trial of a cognitive remediation program for childhood survivors of a pediatric malignancy. J Consult Clin Psychol. 2008;76(3):367–78.
Thompson SJ, Leigh L, Christensen R, Xiong X, Kun LE, Heideman RL, et al. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol. 2001;19(6):1802–8.
Mulhern RK, Khan RB, Kaplan S, Helton S, Christensen R, Bonner M, et al. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol. 2004;22(23):4795–803.
Castellino SM, Tooze JA, Flowers L, Hill DF, McMullen KP, Shaw EG, et al. Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: a pilot study. Pediatr Blood Cancer. 2012;59(3):540–7.
Hardy KK, Willard VW, Allen TM, Bonner MJ. Working memory training in survivors of pediatric cancer: a randomized pilot study. Psychooncology. 2013;22(8):1856–65.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Janzen, L., Mabbott, D., Guger, S.L. (2015). Neuropsychological Outcomes in Pediatric Brain Tumor Survivors. In: Scheinemann, K., Bouffet, E. (eds) Pediatric Neuro-oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1541-5_24
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1541-5_24
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1540-8
Online ISBN: 978-1-4939-1541-5
eBook Packages: MedicineMedicine (R0)